IP Verse

Exendin For Treating Diabetes And Reducing Body Weight - EP2347762

The patent EP2347762 was granted to Amylin Pharmaceuticals on May 8, 2019. The application was originally filed on Aug 18, 2006 under application number EP10016112A. The patent is currently recorded with a legal status of "Revoked".

EP2347762

AMYLIN PHARMACEUTICALS
Application Number
EP10016112A
Filing Date
Aug 18, 2006
Status
Revoked
Dec 15, 2023
Grant Date
May 8, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKFeb 7, 2020ADMISSIBLE
INSTONEJan 21, 2020ADMISSIBLE

Patent Citations (73) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS19960694954-
DESCRIPTIONUS19970055404-
DESCRIPTIONUS19970065442-
DESCRIPTIONUS19970066029-
DESCRIPTIONUS19970349097-
DESCRIPTIONUS19970908867-
DESCRIPTIONUS19980003869-
DESCRIPTIONUS19980075122-
DESCRIPTIONUS19990116380-
DESCRIPTIONUS19990132017-
DESCRIPTIONUS19990323867-
DESCRIPTIONUS20000175365-
DESCRIPTIONUS20000554531-
DESCRIPTIONUS20000622105-
DESCRIPTIONUS20010756690-
DESCRIPTIONUS20010889330-
DESCRIPTIONUS20010889331-
DESCRIPTIONUS20010942631-
DESCRIPTIONUS20020157224-
DESCRIPTIONUS20020419388-
DESCRIPTIONUS20020554533-
DESCRIPTIONUS20030181102-
DESCRIPTIONUS20030688059-
DESCRIPTIONUS20030688786-
DESCRIPTIONUS20040563245-
DESCRIPTIONUS20050055093-
DESCRIPTIONUS20050312371-
DESCRIPTIONUS20050487705-
DESCRIPTIONUS20050522103-
DESCRIPTIONUS20050755005-
DESCRIPTIONUS20060757258-
DESCRIPTIONWO1997US14199-
DESCRIPTIONWO1998US00449-
DESCRIPTIONWO1998US16387-
DESCRIPTIONWO1998US24210-
DESCRIPTIONWO1998US24273-
DESCRIPTIONWO1999US02554-
DESCRIPTIONWO2000US00902-
DESCRIPTIONWO2000US00942-
DESCRIPTIONWO2000US14231-
DESCRIPTIONWO2001US00719-
DESCRIPTIONWO2003US16699-
DESCRIPTIONWO2005US04178-
DESCRIPTIONEP1512395
DESCRIPTIONUS2004053819
DESCRIPTIONUS2005171503
DESCRIPTIONUS2006034889
DESCRIPTIONUS2006034923
DESCRIPTIONUS2006084604
DESCRIPTIONUS5424286
DESCRIPTIONUS5824778
DESCRIPTIONUS5824784
DESCRIPTIONUS6824822
DESCRIPTIONUS6828303
DESCRIPTIONUS6924264
DESCRIPTIONWO2005040195
DESCRIPTIONWO2005041873
DESCRIPTIONWO2005112633
DESCRIPTIONWO2006017852
DESCRIPTIONWO2006041538
OPPOSITIONWO0247716
OPPOSITIONWO03099314
OPPOSITIONWO2004035754
OPPOSITIONWO2004035762
OPPOSITIONWO2004036186
OPPOSITIONWO2005041873
OPPOSITIONWO2005102293
OPPOSITIONWO2005110425
OPPOSITIONWO2007022518
OTHERUS2004228833
SEARCHUS6924264
SEARCHWO2005041873
SEARCHWO2005102293

Non-Patent Literature (NPL) Citations (42) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- Applied Biosystems User's Manual for the ABI 430A Peptide Synthesizer, APPLIED BIOSYSTEMS; INC., (19880701), pages 49 - 70-
DESCRIPTION- BARTLETT; LANDEN, BIORG. CHEM., (1986), vol. 14, pages 356 - 377-
DESCRIPTION- BRAY, ANI. J. CLIN. NUTR., (1992), vol. 55, pages 538S - 544S-
DESCRIPTION- COHEN ET AL., The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, MILLIPORE CORPORATION, (1989), pages 11 - 52-
DESCRIPTION- COLE ET AL., METABOLISRN, (1978), vol. 27, pages 289 - 301-
DESCRIPTION- DAVIS ET AL., DIABETES, (1978), vol. 27, pages 102 - 107-
DESCRIPTION- EISSELE ET AL., LIFE SCI., (1994), vol. 55, pages 629 - 34-
DESCRIPTION- ENG ET AL., J. BIOL. CHEM., (1990), vol. 265, pages 20259 - 62-
DESCRIPTION- ENG ET AL., J. BIOL CHEM., (1992), vol. 267, pages 7402 - 05-
DESCRIPTION- ENG, J. ET AL., J. BIOL. CHEM., (1990), vol. 265, pages 20259 - 62-
DESCRIPTION- ENG., J. ET AL., J BIOL. CHEM., (1992), vol. 267, pages 7402 - 05-
DESCRIPTION- ENG., J. ET AL., J. BIOL. CHEM., (1992), vol. 267, pages 7402 - 05-
DESCRIPTION- FINEMAN ET AL., DIABETES CARE, (2003), vol. 26, pages 2370 - 2377-
DESCRIPTION- GOKE ET AL., J. BIOL. CHEM., (1993), vol. 268, pages 19650 - 55-
DESCRIPTION- GOKE ET AL., J. BIOL. CLIEM., (1993), vol. 268, pages 19650 - 55-
DESCRIPTION- JUNG; CHONG, CLINICAL ENDOCRINOLOGY, (1991), vol. 35, pages 11 - 20-
DESCRIPTION- LEE ET AL., CLIN. PEDIATR., (1992), vol. 3, no. 1, pages 234 - 236-
DESCRIPTION- MALHOTRA, R. ET AL., REGULATORY PEPTIDES, (1992), vol. 41, pages 149 - 56-
DESCRIPTION- RAUFINAN ET AL., J. BIOL. CHEM., (1992), vol. 267, pages 21432 - 37-
DESCRIPTION- RAUFMAN ET AL., J. BIOL. CHEM., (1992), vol. 267, pages 21432 - 37-
DESCRIPTION- SCHEPP ET AL., EUR. J. PHARMACOL., (1994), vol. 69, pages 183 - 91-
DESCRIPTION- SINGH ET AL., REGULATORY PEPTIDES., (1994), vol. 53, pages 47 - 59-
DESCRIPTION- WATERMAN, BULL. MATH. BIOL., (1984), vol. 46, page 473-
DESCRIPTION- LUCKE ET AL., "Peptide Acylation by Poly(a-Hydroxy Esters)", PHARMACEUTICAL RESEARCH, (200202), vol. 19, no. 2, doi:doi:10.1023/A:1014272816454, pages 175 - 181, XP009021677
OPPOSITION- Anonymous, 38th Annual EASD Meeting Abstract OP21 Talk 23, (20020903), XP055675783-
OPPOSITION- Anonymous, Byetta@ Clinical Pharmacology Biopharmaceutics Review(s, (20050804), URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_ByettaTOC.cfm, XP055675777-
OPPOSITION- Anonymus, "Chapter 7.14 Drug Delivery Systems", Biomaterials Science -An Introduction to Materials in Medicine, Elsevier Academic Press, (20040101), pages 628 - 648, XP055675795-
OPPOSITION- "Assessment report for Bydureon Procedure no. EMEA/H/C/002020", EMA, (2011), pages 1 - 69, XP055683869-
OPPOSITION- Bogentoft et al., "Controlled release from dosage forms", Bogentoft et al., D D Breimer, Towards Better Safety of Drugs and Pharmaceutical Products, pages 229 - 246, XP055684047-
OPPOSITION- Bray, Grant, "Formulary Review Exenatide", Am J Health-Syst Pharm, (20060301), vol. 63, pages 411 - 418, XP055675748-
OPPOSITION- "Exenatide LAR data support initiation of phase 2 multi-dose study in 2005", Amylin Pharmaceutical Press Release-
OPPOSITION- "Incretin-based therapies in type 2 diabetes: an expert interview with John B Buse", Medscape Diabetes & Endocrinology, (2006), URL: https://www.medscape.org/viewarticle/537094, XP055683823-
OPPOSITION- LILLY, "Once Weekly Exenatide LAR Well Tolerated and Improved Glucose Control", Press Release, (20050822), XP055675764-
OPPOSITION- LILLY, "Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes", Press Release, (20060610), XP055675770-
OPPOSITION- S Proudfoot, "Dosage regimens: their influence on the concentration-time profile of a drug in the body", Pharmaceutics- The Science of Dosage Form Design, (19880101), pages 191 - 211, XP055675792-
OPPOSITION- Cohen et al., "Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid", Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid, (19910601), vol. 8, pages 713 - 720, XP002001157
OPPOSITION- Fineman, "Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing", CLINICAL PHARMACOKINETICS, (2011), pages 65 - 74, XP055442145
OPPOSITION- Defronzo et al., "Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes", DIABETES CARE, (20050501), vol. 28, pages 1092 - 1100, XP055554757
SEARCH- AMYLIN PHARMACEUTICALS PRESS RELEASES, "Exenatide LAR data support initiation of phase 2 multi-dose study in 2005", INTERNET ARTICLE, (20041102), URL: www.amylin.com, (20070502), XP002431950 [A] 1-16 * the whole document *-
SEARCH- GEDULIN B R ET AL, "Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats.", DIABETOLOGIA JUL 2005, (200507), vol. 48, no. 7, ISSN 0012-186X, pages 1380 - 1385, XP002431948 [X] 1-16 * abstract *
SEARCH- "EXENATIDE: AC 2993, AC002993, AC2993A, EXENDIN 4, LY2148568", DRUGS IN R & D, ADIS INTERNATIONAL, AUCKLAND, NZ, (2004), vol. 5, no. 1, ISSN 1174-5886, pages 35 - 40, XP009083108 [A] 1-16 * abstract *
SEARCH- BUSE JOHN B ET AL, "Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.", DIABETES CARE NOV 2004, (200411), vol. 27, no. 11, ISSN 0149-5992, pages 2628 - 2635, XP002431949 [A] 1-16 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents